ArticleClinical, cosmetic and investigational dermatology2026
Efficacy Evaluation of N-Acyl-Phytosphingosine Prepared from Marula Oil Derived Fatty Acids in Skin Barrier Repair.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to assess the efficacy of a novel N-acyl-phytosphingosine prepared from marula oil derived fatty acids (MO-CER NPs) in repairing impaired skin barrier function. Patients and Methods: MO-CER NPs were synthesized from N-acyl-phytosphingosine using marula oil as a fatty acid source. Their effects on skin barrier improvement were compared with those of conventional C18-CER NP. A 28-day clinical trial involving 32 subjects was conducted to evaluate the efficacy of a topical cream containing 0.05% MO-CER NPs on barrier-compromised skin. Results: Treatment with MO-CER NPs alleviated UVB-induced barrier damage as effectively as C18-CER NP, evidenced by increased expression of filaggrin and loricrin and reduced count of sunburn cells. Notably, MO-CER NPs showed superior anti-inflammatory activity. Furthermore, MO-CER NPs upregulated key genes involved in ceramide biosynthesis, keratinocyte proliferation, and differentiation. The clinical trial confirmed that topical application of 0.05% MO-CER NPs significantly improved barrier function by reducing transepidermal water loss and erythema, while increasing skin thickness and density. Conclusion: MO-CER NPs demonstrated superior efficacy over conventional C18-CER NP in ameliorating skin barrier dysfunction and inflammation, highlighting its potential for improving barrier-compromised skin conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.